Scorpius Holdings, Inc. Stock

Equities

SCPX

US42237K4094

Pharmaceuticals

Delayed Nyse 11:18:37 2024-04-23 am EDT 5-day change 1st Jan Change
0.158 USD -0.32% Intraday chart for Scorpius Holdings, Inc. -0.32% -64.12%
Sales 2023 * 4.9M Sales 2024 * 20.6M Capitalization 5.71M
Net income 2023 * -44M Net income 2024 * -22M EV / Sales 2023 * 1.17 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.28 x
P/E ratio 2023 *
-0.1 x
P/E ratio 2024 *
-0.25 x
Employees 77
Yield 2023 *
-
Yield 2024 *
-
Free-Float 94.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.47%
Current month-2.16%
1 month-0.94%
3 months-56.09%
6 months-61.81%
Current year-64.00%
More quotes
1 week
0.16
Extreme 0.157
0.17
1 month
0.16
Extreme 0.156
0.18
Current year
0.15
Extreme 0.145
0.53
1 year
0.15
Extreme 0.145
0.89
3 years
0.15
Extreme 0.145
10.85
5 years
0.15
Extreme 0.145
30.10
10 years
0.15
Extreme 0.145
763.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 08-06-09
Director of Finance/CFO 56 19-09-24
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 16-04-25
Chief Executive Officer 60 08-06-09
Director/Board Member 48 08-12-31
More insiders
Date Price Change Volume
24-04-23 0.158 -0.32% 112 249
24-04-22 0.1585 +0.96% 210,804
24-04-19 0.157 -1.01% 144,935
24-04-18 0.1586 -1.06% 212,110
24-04-17 0.1603 +1.14% 254,749

Delayed Quote Nyse, April 22, 2024 at 04:00 pm EDT

More quotes
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.1585 USD
Average target price
10 USD
Spread / Average Target
+6,209.15%
Consensus